Korah, Boots and Wieder reconstituted an in vitro paradigm of breast cancer dormancy in bone marrow: FGF-2 (10 ng/mL) completely suppressed clonogenic growth of well-differentiated MCF-7 and T-47D cells (EGF had no effect; MDA-MB-231 was unresponsive) yet spared small, spread-out dormant clones whose survival was selectively supported by fibronectin . Up to day 15, fibronectin-supported dormant clones reached 249% (MCF-7) and 305% (T-47D) of tissue-culture-plastic controls, versus 55%/57% on collagen I and 32%/99% on collagen IV — despite cells adhering to all three substrates. Function-blocking GRGDSP peptide against fibronectin reduced dormant clones by 63.6% (MCF-7) and 50.1% (T-47D; P<0.001), with TUNEL positivity showing deaths were apoptotic; the GRGESP control peptide was inert .
Mechanistically, FGF-2 up-regulated α5, β1, α2, β3 and β4 integrins at mRNA and protein levels within 3–5 days; an α5 antibody blocked fibronectin adhesion by ~75% in FGF-2-treated versus ~33% in untreated cells, while α2β1 blockade left fibronectin adhesion intact . Critically, MDA-MB-231 carries constitutively high α5 yet neither enters dormancy nor responds to FGF-2 — so α5 expression alone is insufficient, implicating differentiation state and ligation competence. Removing FGF-2 after day 3 converted dormant clones into growing colonies by day 9 on fibronectin (absent when FGF-2 was maintained), demonstrating dormancy is reversible and cells retain clonogenic capacity.
FGF-2 sustained Akt phosphorylation on fibronectin in MCF-7/T-47D (strongest at 24 h, sustained ≥5 days) but not in MDA-MB-231. Akt inhibitor I reduced dormant clones dose-dependently with ED50 5 µM (matching the reported Kd), and LY294002 with ED50 ≈10 µM; neither eradicated dormant clones below the plastic-supported baseline . Two dissociations strengthen causality: Akt inhibition spared the characteristic spread dormant morphology whereas LY294002 survivors became small, dendritic and distressed (implying Akt-independent, PI3K-downstream pathways control cytoskeletal dormancy traits), and LY294002 inhibited growing clones more potently (~5 µM) while the Akt inhibitor largely spared them. In human marrow stromal cocultures, T-47D/MCF-7 growth was restricted to 4–8-cell clones while MDA-MB-231 proliferated; stromal FGF-2 was confirmed by Western blot; a fibronectin-blocking peptide reduced dormant clone survival on stroma without harming stromal cells, and LY294002 spared stromal monolayers .
The FGF-2–α5β1–fibronectin–PI3K/Akt axis would be falsified if blocking fibronectin ligation or PI3K/Akt failed to affect dormant clone survival, if dormancy occurred independently of fibronectin engagement, or if MDA-MB-231 entered dormancy under identical conditions. Confidence in the in vitro mechanism is moderate-to-high; confidence that it explains clinical marrow dormancy is low pending in vivo testing, and the era's reliance on LY294002-class inhibitors warrants modern genetic replication (ITGA5/ITGB1 CRISPR, Akt isoform-specific knockdown). This is BGPT's critical inference, not an author claim.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.